A new study, published in the European Heart Journal, establishes imidazole propionate (ImP), a gut microbiota-derived molecular driver of vascular inflammation and atherosclerosis, as a novel nontraditional cardiovascular risk factor in patients with coronary artery disease.
Watch the short video & get the full article here!
Subscribe to InsideCardiology here!